{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:18:03Z","timestamp":1775067483989,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.7759\/cureus.106280","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:38:19Z","timestamp":1775061499000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 Receptor Agonists Reduce Liver Stiffness in a Pediatric Metabolic Dysfunction-Associated Liver Disease Cohort and Normalize Disease-Associated Core Gene Expression in an Experimental Model"],"prefix":"10.7759","author":[{"given":"Ella","family":"Findling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence","family":"Bissoondial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103505","article-title":"Evaluation of defensins as markers of gut microbiota disturbances in children with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"14","author":"Wierzbicka-Ruci\u0144ska A","year":"2025","unstructured":"Wierzbicka-Ruci\u0144ska A, Konopka E, Wi\u0119ckowski S, et al.. Evaluation of defensins as markers of gut microbiota disturbances in children with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). J Clin Med. 2025, 14:3505. 10.3390\/jcm14103505","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2508951","article-title":"Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH","volume":"17","author":"Z\u00f6ggeler T","year":"2025","unstructured":"Z\u00f6ggeler T, Kavallar AM, Pollio AR, et al.. Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH. Gut Microbes. 2025, 17:2508951. 10.1080\/19490976.2025.2508951","journal-title":"Gut Microbes"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12346","article-title":"Environmental toxicants modulate disease severity in pediatric metabolic dysfunction-associated steatohepatitis","volume":"79","author":"Jain AK","year":"2024","unstructured":"Jain AK, Busgang SA, Gennings C, et al.. Environmental toxicants modulate disease severity in pediatric metabolic dysfunction-associated steatohepatitis. J Pediatr Gastroenterol Nutr. 2024, 79:943-53. 10.1002\/jpn3.12346","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v18.i1.111211","article-title":"Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: role of non-invasive diagnostics and early pharmacological intervention","volume":"18","author":"Ng NB","year":"2026","unstructured":"Ng NB, Sng AA, Huang JG. Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: role of non-invasive diagnostics and early pharmacological intervention. World J Hepatol. 2026, 18:111211. 10.4254\/wjh.v18.i1.111211","journal-title":"World J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001440","article-title":"Call to action-pediatric MASLD requires immediate attention to curb health crisis","volume":"82","author":"Hartmann P","year":"2025","unstructured":"Hartmann P, Mouzaki M, Hassan S, et al.. Call to action-pediatric MASLD requires immediate attention to curb health crisis. Hepatology. 2025, 82:1341-51. 10.1097\/HEP.0000000000001440","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12525","article-title":"Therapeutic management of metabolic dysfunction associated steatotic liver disease","volume":"12","author":"Zeng J","year":"2024","unstructured":"Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United European Gastroenterol J. 2024, 12:177-86. 10.1002\/ueg2.12525","journal-title":"United European Gastroenterol J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2024.0442","article-title":"Prediction model for insulin resistance and implications for MASLD in youth: a novel marker, the pediatric insulin resistance assessment score","volume":"66","author":"Song K","year":"2025","unstructured":"Song K, Lee E, Youn YH, et al.. Prediction model for insulin resistance and implications for MASLD in youth: a novel marker, the pediatric insulin resistance assessment score. Yonsei Med J. 2025, 66:464-72. 10.3349\/ymj.2024.0442","journal-title":"Yonsei Med J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198937","article-title":"Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; an OAD to NASH","volume":"13","author":"Hwang A","year":"2018","unstructured":"Hwang A, Shi C, Zhu E, et al.. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; an OAD to NASH. PLoS One. 2018, 13:e0198937. 10.1371\/journal.pone.0198937","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.0c02350","article-title":"Glycerol-3-phosphate acyltransferase1 is a model-agnostic node in nonalcoholic fatty liver disease: implications for drug development and precision medicine","volume":"5","author":"Liao K","year":"2020","unstructured":"Liao K, Pellicano AJ, Jiang K, et al.. Glycerol-3-phosphate acyltransferase1 is a model-agnostic node in nonalcoholic fatty liver disease: implications for drug development and precision medicine. ACS Omega. 2020, 5:18465-71. 10.1021\/acsomega.0c02350","journal-title":"ACS Omega"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27387","article-title":"Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces","volume":"61","author":"Simonetto DA","year":"2015","unstructured":"Simonetto DA, Yang HY, Yin M, et al.. Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces. Hepatology. 2015, 61:648-59. 10.1002\/hep.27387","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00254.2021","article-title":"Stiffness is associated with hepatic stellate cell heterogeneity during liver fibrosis","volume":"322","author":"Kostallari E","year":"2022","unstructured":"Kostallari E, Wei B, Sicard D, et al.. Stiffness is associated with hepatic stellate cell heterogeneity during liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2022, 322:G234-46. 10.1152\/ajpgi.00254.2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-021-03269-4","article-title":"Liver fibrosis assessment: MR and US elastography","volume":"47","author":"Ozturk A","year":"2022","unstructured":"Ozturk A, Olson MC, Samir AE, Venkatesh SK. Liver fibrosis assessment: MR and US elastography. Abdom Radiol (NY). 2022, 47:3037-50. 10.1007\/s00261-021-03269-4","journal-title":"Abdom Radiol (NY)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2022.9214\/2022","article-title":"Non-invasive liver fibrosis assessment: is transient elastography mandatory?","volume":"115","author":"Azevedo Silva M","year":"2023","unstructured":"Azevedo Silva M, Leal C, Gon\u00e7alves AR, et al.. Non-invasive liver fibrosis assessment: is transient elastography mandatory?. Rev Esp Enferm Dig. 2023, 115:394-5. 10.17235\/reed.2022.9214\/2022","journal-title":"Rev Esp Enferm Dig"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1007\/s13312-023-3066-z","article-title":"Indian Academy of Pediatrics revised guidelines on evaluation, prevention and management of childhood obesity","volume":"60","author":"Khadilkar V","year":"2023","unstructured":"Khadilkar V, Shah N, Harish R, et al.. Indian Academy of Pediatrics revised guidelines on evaluation, prevention and management of childhood obesity. Indian Pediatr. 2023, 60:1013-31.","journal-title":"Indian Pediatr"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194749","article-title":"GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity","volume":"135","author":"Cooper ME","year":"2025","unstructured":"Cooper ME, van Raalte DH. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest. 2025, 135:10.1172\/JCI194749","journal-title":"J Clin Invest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073832","article-title":"Glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: novel medication in new liver disease nomenclature","volume":"25","author":"Chrysavgis LG","year":"2024","unstructured":"Chrysavgis LG, Kazanas S, Bafa K, Rozani S, Koloutsou ME, Cholongitas E. Glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: novel medication in new liver disease nomenclature. Int J Mol Sci. 2024, 25:3832. 10.3390\/ijms25073832","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5009\/gnl240198","article-title":"Combi-elastography versus transient elastography for assessing the histological severity of metabolic dysfunction-associated steatotic liver disease","volume":"18","author":"Lee YK","year":"2024","unstructured":"Lee YK, Lee DH, Joo SK, et al.. Combi-elastography versus transient elastography for assessing the histological severity of metabolic dysfunction-associated steatotic liver disease. Gut Liver. 2024, 18:1048-59. 10.5009\/gnl240198","journal-title":"Gut Liver"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64447","article-title":"Navigating disease management: a comprehensive review of the de ritis ratio in clinical medicine","volume":"16","author":"Shaikh SM","year":"2024","unstructured":"Shaikh SM, Varma A, Kumar S, Acharya S, Patil R. Navigating disease management: a comprehensive review of the de ritis ratio in clinical medicine. Cureus. 2024, 16:e64447. 10.7759\/cureus.64447","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar R","year":"2002","unstructured":"Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30:207-10. 10.1093\/nar\/30.1.207","journal-title":"Nucleic Acids Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116888","article-title":"Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity","volume":"176","author":"McGlone ER","year":"2024","unstructured":"McGlone ER, Hope DC, Davies I, et al.. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity. Biomed Pharmacother. 2024, 176:116888. 10.1016\/j.biopha.2024.116888","journal-title":"Biomed Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02257-1","article-title":"GepLiver: an integrative liver expression atlas spanning developmental stages and liver disease phases","volume":"10","author":"Li Z","year":"2023","unstructured":"Li Z, Zhang H, Li Q, et al.. GepLiver: an integrative liver expression atlas spanning developmental stages and liver disease phases. Sci Data. 2023, 10:376. 10.1038\/s41597-023-02257-1","journal-title":"Sci Data"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-025-02994-8","article-title":"HumanBase: an interactive AI platform for human biology","volume":"23","author":"Sealfon RS","year":"2026","unstructured":"Sealfon RS, Theesfeld CL, Funk J, Sauerwald N, Wong AK, Troyanskaya OG. HumanBase: an interactive AI platform for human biology. Nat Methods. 2026, 23:483-4. 10.1038\/s41592-025-02994-8","journal-title":"Nat Methods"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.14738","article-title":"Bioinformatic prediction of the molecular links between Alzheimer's disease and diabetes mellitus","volume":"11","author":"Castillo-Vel\u00e1zquez R","year":"2023","unstructured":"Castillo-Vel\u00e1zquez R, Mart\u00ednez-Morales F, Casta\u00f1eda-Delgado JE, et al.. Bioinformatic prediction of the molecular links between Alzheimer's disease and diabetes mellitus. PeerJ. 2023, 11:e14738. 10.7717\/peerj.14738","journal-title":"PeerJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-023-04170-3","article-title":"Liver transient elastography values in healthy South African children","volume":"23","author":"Rose PC","year":"2023","unstructured":"Rose PC, Cotton MF, Otwombe K, Innes S, Nel ED. Liver transient elastography values in healthy South African children. BMC Pediatr. 2023, 23:355. 10.1186\/s12887-023-04170-3","journal-title":"BMC Pediatr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera L","year":"2008","unstructured":"Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008, 48:835-47. 10.1016\/j.jhep.2008.02.008","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi T","year":"2017","unstructured":"Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017, 121:27-42. 10.1016\/j.addr.2017.05.007","journal-title":"Adv Drug Deliv Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2017.32.1.1","article-title":"New potential targets of glucagon-like peptide 1 receptor agonists in pancreatic \u03b2-cells and hepatocytes","volume":"32","author":"Lee WY","year":"2017","unstructured":"Lee WY. New potential targets of glucagon-like peptide 1 receptor agonists in pancreatic \u03b2-cells and hepatocytes. Endocrinol Metab (Seoul). 2017, 32:1-5. 10.3803\/EnM.2017.32.1.1","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010026","article-title":"Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling","volume":"19","author":"Oh YS","year":"2017","unstructured":"Oh YS, Jun HS. Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. Int J Mol Sci. 2017, 19:26. 10.3390\/ijms19010026","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1763185","article-title":"Glucagon-like peptide-1 and dual\/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research","volume":"13","author":"Lu X","year":"2026","unstructured":"Lu X, Yang L. Glucagon-like peptide-1 and dual\/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research. Front Med (Lausanne). 2026, 13:1763185. 10.3389\/fmed.2026.1763185","journal-title":"Front Med (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/476709-glucagon-like-peptide-1-receptor-agonists-reduce-liver-stiffness-in-a-pediatric-metabolic-dysfunction-associated-liver-disease-cohort-and-normalize-disease-associated-core-gene-expression-in-an-experimental-model","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:38:20Z","timestamp":1775061500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/476709-glucagon-like-peptide-1-receptor-agonists-reduce-liver-stiffness-in-a-pediatric-metabolic-dysfunction-associated-liver-disease-cohort-and-normalize-disease-associated-core-gene-expression-in-an-experimental-model"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.106280","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}